We knew there had to be a way to increase the effectiveness of traditional cancer therapies. One that leverages what we know about viruses and how they attack cells and use that information to attack and kill cancer cells. We believe in a world without cancer, this is what drives us, this is our mission.
Calidi Biotherapeutics is focused on the optimized delivery of oncolytic viruses. This is a promising new approach to the treatment of solid tumors and hematological malignancies, with minimal toxicity and improved tolerability as compared to conventional treatments. Our proprietary immunotherapy platform and delivery methods can transform the way cancer is treated. We are currently working with the Food and Drug Administration (FDA) on an Investigational New Drug (IND) application to commence a Phase 1b/2a clinical trial for our leading product candidate.